Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/11/2026

1. SPCX
2. HUM
3. ALHC
4. T
5. PEP
6. UNH
7. AXP
8. TMUS
9. SPY
10. CVS

Go back to Arcutis Biotherapeutics, Inc. (ARQT) Tops Q2 EPS by 9c

Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update

August 14, 2024 4:00 PM EDT

Second quarter net product revenues for ZORYVE® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q2 '23 and 43% vs. Q1 '24Continued gross-to-net (GTN) improvement with blended GTN across products now in the high 50 percent range, improving from the low 60 percent range last quarterSustained growth in prescriptions for both cream and foam, with total U.S. franchise unit demand increase of 42% quarter over quarterEntered into ZORYVE co-promotion agreement with Kowa Pharmaceuticals America, Inc., expanding promotional efforts to... More